Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than-expected fourth-quarter revenues for the drug.
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Lilly's fourth-quarter earnings, released before the market opened Thursday, surpassed analysts' expectations by millions.
Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback